Effect of pimobendan or benazepril hydrochloride on survival times in
dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
Effect of pimobendan or benazepril hydrochloride on survival times in
dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST Study.
Not exact matches
In the QUEST Study, pimobendan significantly increased the survival time of
dogs with congestive heart failure (CHF)
caused by myxomatous mitral valve disease (MMVD).
The QUEST Study established pimobendan as the new standard of treatment for
dogs with congestive heart failure (CHF)
caused by MMVD as it extended survival time.2 The veterinary community also sought to answer this question: Can pimobendan also delay the onset of clinical signs of CHF?
This groundbreaking study sought to answer a key question: Can pimobendan —
with proven efficacy in treating
dogs with congestive heart failure (CHF)
caused by myxomatous mitral valve disease (MMVD)-- also delay the onset of CHF
caused by MMVD?
The aim of this study was to evaluate the efficacy of pimobendan
with conventional therapies on survival and reocurrence of pulmonary edema in
dogs with congestive heart failure (CHF)
caused by myxomatous mitral valve disease (MMVD).